A Phase 3 interventional study of Pregabalin and Placebo in Sleep Deprivation and Epilepsies, Partial, sponsored by Pfizer. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-24.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the effects of pregabalin on sleep problems in patients with seizures.
314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.
This study's enrollment of 17 is below the median of 50 across 259 interventional studies indexed under Sleep Deprivation.
Browse Sleep Deprivation studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Pregabalin
Drug: Placebo
Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
Matching placebo capsules twice daily for 28 days
Change from baseline in polysomnographic (PSG) sleep efficiency in the efficacy evaluable population
Time frame: Endpoint
Change from baseline in total sleep time
Time frame: Endpoint
Change from baseline in sleep onset latency
Time frame: Endpoint
Change from baseline in wake after sleep onset
Time frame: Endpoint
Change from baseline in percent sleep spent in stages 3 and 4
Time frame: Endpoint
Change from baseline in percent sleep spent in REM stage
Time frame: Endpoint
Change from baseline in night sleep quality based on Groningen Sleep Questionnaire (GSQ)
Time frame: Endpoint
Change from baseline in 4-week sleep quality (Medical Outcomes Study [MOS] Sleep Scale)
Time frame: Endpoint
Adverse events and laboratory value changes
Time frame: Endpoint
The record gives a start of Nov 2002 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin